From what 0 stock analysts predict, the share price for Danimer Scientific (DNMR) might decrease by 92.58% in the next year. This is based on a 12-month average estimation for DNMR. Price targets go from $0.4 to $1. The majority of stock analysts believe DNMR is a sell. Please note analyst price targets are not guaranteed and could be missed completely.
About 0 Wall Street analysts have assignedDNMR 0 buy ratings, 0 hold ratings, and 0 sell ratings. This means that analysts expect Danimer Scientific to sell. Keep in mind that these ratings are typically refreshed every quarter, underscoring the importance of conducting your own research on DNMR. Don't forget to include both technical and fundamental analysis, as well as staying informed on news that could influence these ratings, in your due diligence.
These are the latest 20 analyst ratings of DNMR.
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
---|---|---|---|---|
Charles Neivert Piper Sandler | Neutral | $1 | Maintains | Aug 21, 2024 |
TD Cowen | Hold | Downgrade | Aug 13, 2024 | |
Laurence Alexander Jefferies | Hold | $0.8 | Downgrade | May 22, 2024 |
Charles Neivert Piper Sandler | Neutral | $1.25 | Downgrade | Apr 9, 2024 |
Thomas Boyes TD Cowen | Buy | $2 | Maintains | Apr 4, 2024 |
Charles Neivert Piper Sandler | Overweight | $4 | Maintains | Oct 11, 2023 |
Charles Neivert Piper Sandler | Overweight | $8 | Maintains | Jun 1, 2023 |
Charles Neivert Piper Sandler | Overweight | $7 | Maintains | Apr 3, 2023 |
Charles Neivert Piper Sandler | Overweight | $4.5 | Initiates | Oct 12, 2022 |
Thomas Boyes Cowen & Co. | Outperform | $21 | Initiates | Sep 23, 2021 |
When did it IPO
2012
Staff Count
257
Country
United States
Sector/Industry
Basic Materials/Specialty Chemicals
CEO
Mr. Stephen E. Croskrey
Market Cap
$30.2M
In 2023, DNMR generated $46.7M in revenue, which was a decrease of -12.28% from the previous year. This can be seen as a signal that DNMR's business is declining, and its share price could be worth less in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2020
Revenue From 2021
Revenue From 2022
Revenue From 2023
Summary - Danimer Scientific, Inc. will implement a 1-for-40 reverse stock split for its Class A common stock, following approval from stockholders and its Board of Directors.
Why It Matters - The reverse stock split indicates a restructuring effort, potentially aimed at increasing share price and attracting institutional investors, impacting liquidity and market perception.
Summary - Danimer Scientific's putative class action complaint was dismissed by the U.S. Court of Appeals for the Second Circuit, affirming a 2023 District Court ruling.
Why It Matters - The court's dismissal of the class action lawsuit reduces legal risks for Danimer Scientific, potentially stabilizing its stock and attracting investor confidence in its bioplastics business.
Summary - Danimer Scientific has appointed Richard Altice as Interim CEO, succeeding Stephen Croskrey, who is retiring. Altice is a current director and former CEO of NatureWorks.
Why It Matters - Leadership changes can impact a company's strategic direction and operational performance, influencing investor confidence and stock prices.
Summary - Danimer Scientific (NYSE: DNMR) received a $1.36 million award from the U.S. Department of Defense to develop a facility for producing biobased polyols for high-performance coatings.
Why It Matters - Danimer Scientific's $1.36 million award from the U.S. Department of Defense enhances its credibility and funding, potentially boosting revenue and market position in biomaterials.
Summary - Danimer Scientific (NYSE: DNMR) and Ningbo Homelink have launched home compostable coatings made from Danimer's PHA, Nodaxยฎ, for disposable tableware.
Why It Matters - The launch of home compostable biopolymers by Danimer and Homelink signals growing demand for sustainable products, potentially enhancing market share and revenue, which can positively impact stock performance.
Summary - Danimer Scientific (DNMR) has received a Zacks Rank #2 (Buy), indicating increasing optimism about its earnings prospects, which may lead to potential stock price growth.
Why It Matters - The upgrade to Zacks Rank #2 indicates positive sentiment around Danimer Scientific's earnings, suggesting potential stock price appreciation and increased investor confidence.